Dutrebis is a drug owned by Merck Sharp And Dohme Corp. It is protected by 9 US drug patents filed from 2015 to 2017. Out of these, 2 drug patents are active and 7 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 11, 2029. Details of Dutrebis's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US7754731 | Potassium salt of an HIV integrase inhibitor |
Mar, 2029
(3 years from now) | Active |
| US7169780 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2023
(1 year, 7 months ago) |
Expired
|
| US7820660 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(2 years ago) |
Expired
|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US7754731 (Pediatric) | Potassium salt of an HIV integrase inhibitor |
Sep, 2029
(4 years from now) | Active |
|
US7169780 (Pediatric) | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2024
(1 year, 1 month ago) |
Expired
|
|
US7217713 (Pediatric) | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(2 years ago) |
Expired
|
|
US7435734 (Pediatric) | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(2 years ago) |
Expired
|
| US7217713 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(2 years ago) |
Expired
|
| US7435734 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(2 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Dutrebis's patents.
Latest Legal Activities on Dutrebis's Patents
Given below is the list of recent legal activities going on the following patents of Dutrebis.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 09 Mar, 2022 | US7820660 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 09 Dec, 2021 | US7754731 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 16 Mar, 2020 | US7435734 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 16 Oct, 2018 | US7217713 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 12 Jun, 2018 | US7169780 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Mar, 2018 | US7820660 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 Dec, 2017 | US7754731 |
| Post Issue Communication - Certificate of Correction | 30 Mar, 2011 | US7169780 |
| Record a Petition Decision of Granted for Patent Term Adjustment after Issue | 25 Jan, 2011 | US7169780 |
| Adjustment of PTA Calculation by PTO | 25 Jan, 2011 | US7169780 |
US patents provide insights into the exclusivity only within the United States, but Dutrebis is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Dutrebis's family patents as well as insights into ongoing legal events on those patents.
Dutrebis's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Dutrebis's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 11, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Dutrebis Generics:
There are no approved generic versions for Dutrebis as of now.
Alternative Brands for Dutrebis
Dutrebis which is used for managing HIV-1 infection., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Gilead Sciences Inc |
| |||
| Msd Sub Merck |
| |||
About Dutrebis
Dutrebis is a drug owned by Merck Sharp And Dohme Corp. It is used for managing HIV-1 infection. Dutrebis uses Lamivudine; Raltegravir Potassium as an active ingredient. Dutrebis was launched by Merck Sharp Dohme in 2015.
Approval Date:
Dutrebis was approved by FDA for market use on 06 February, 2015.
Active Ingredient:
Dutrebis uses Lamivudine; Raltegravir Potassium as the active ingredient. Check out other Drugs and Companies using Lamivudine; Raltegravir Potassium ingredient
Treatment:
Dutrebis is used for managing HIV-1 infection.
Dosage:
Dutrebis is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 150MG;EQ 300MG BASE | TABLET | Discontinued | ORAL |